Radium 223 Therapy

INDICATIONS FOR USE:

<table>
<thead>
<tr>
<th>INDICATION</th>
<th>ICD10</th>
<th>Regimen Code</th>
<th>*Reimbursement Status</th>
</tr>
</thead>
<tbody>
<tr>
<td>As monotherapy or in combination with LHRH analogues for the treatment of</td>
<td></td>
<td>C61</td>
<td>ODMS</td>
</tr>
<tr>
<td>adults with progressive castration-resistant metastatic prostate cancer</td>
<td></td>
<td>00257a</td>
<td></td>
</tr>
<tr>
<td>(mCRPC), symptomatic bone metastases and no extensive visceral metastases</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>after at least two prior lines of systemic therapy for mCRPC (other than</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>LHRH analogues), or ineligible for any available licensed systemic mCRPC</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>treatment</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

If the reimbursement status is not defined, the indication has yet to be assessed through the formal HSE reimbursement process.

TREATMENT:

The continuation of the drug details below may be adjusted by prescribing clinician, using their independent medical judgement, to consider each patient individual clinical circumstances.

Radium 223 is administered IV, once every 28 days for 6 injections or until disease progression or unacceptable toxicity develops.

Safety and efficacy beyond 6 injections have not been studied.

It should be administered only by persons authorised to handle radiopharmaceuticals in designated clinical settings which satisfy radiation safety and regulation requirements.

<table>
<thead>
<tr>
<th>Day</th>
<th>Drug</th>
<th>Dose</th>
<th>Route</th>
<th>Diluent &amp; Rate</th>
<th>Cycle</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Radium 223</td>
<td>55kBq/kg</td>
<td>IV</td>
<td>Slow injection up to 1 min</td>
<td>Repeat every 28 days</td>
</tr>
</tbody>
</table>

The IV access line or cannula must be flushed with 0.9% sodium chloride for injection before and after injection of Radium 223.

Prescribers and persons administering radium 223 should be aware that the National Institute of Standards and Technology (NIST) has revised in 2015 the primary standardization for radium-223, referred to as the NIST 2015-traceable reference material.

As a result the numerical value of the radioactivity concentration (in Bq/mL) contained in vials of Xofigo and hence the patient dose in Bq/kg body weight will increase by approx. 10%:

- an increase of the nominal value for the radioactivity from 1000 kBq/mL to 1100 kBq/mL at reference date
- an apparent increase in patient dose, from 50 kBq/kg body weight to 55 kBq/kg body weight

This does not reflect a real change in the actual product radioactivity or in the amount of radioactivity given to the patient and therefore will not impact the safety and efficacy of Xofigo (radium-223 dichloride).

Starting from April 14, 2016, Xofigo product manufactured, tested, and released according to the updated NIST 2015-traceable reference material will be distributed.

The Xofigo product information has been updated to reflect the numerical change of the radioactivity concentration.

The dose to be administered to a given patient should be calculated using the:

- Patient’s body weight (kg)
- Dosage level (55 kBq/kg body weight)
- Radioactivity concentration of the product (1100 kBq/mL) at reference date.
  The reference date is stated on the vial and lead pot label.
- Decay correction (DK) factor to correct for physical decay of radium-223.
  A table of DK factors is provided with each vial as part of the booklet (preceding the package leaflet).
- The amount of radioactivity in the dispensed volume shall be confirmed by measurement in a properly calibrated activimeter.

The total volume to be administered to a patient is calculated as follows:

Volume to be administered (mL) = Body weight (kg) x activity (55 kBq/kg body weight)
The information contained in this document is a statement of consensus of NCCP and ISMO professionals regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult these documents is expected to use independent medical judgement in the context of individual clinical circumstances to determine any patient’s care or treatment. Use of these documents is the responsibility of the prescribing clinician and is subject to HSE’s terms of use available at http://www.hse.ie/eng/Disclaimer.

This information is valid only on the day of printing, for any updates please check www.hse.ie/NCCPchemoprotocols

**ELIGIBILITY:**
- Indications as above including
  - two prior lines of systemic therapy for mCRPC (other than LHRH analogues), or ineligible for any available systemic mCRPC treatment
- Age ≥ 18
- ECOG status 0-2.
- Life expectancy > 6 months.
- Progressive castration resistant metastatic prostate carcinoma disease, defined by a testosterone level ≤ 1.7 nmol/L, and a PSA > 5 preceded by two consecutive rises (at least 1 week apart)
- Detectable (≥ 2 detectable bone lesions on bone scan, done within previous 12 weeks) and symptomatic bone metastases, defined by requirement for analgesic medication and/or palliative radiotherapy within previous 12 weeks
- No visceral metastasis and/or extensive metastatic lymphadenopathies on CT scan (done within previous 12 weeks)
- Adequate bone marrow reserve defined by:
  - Prior treatment initiation and 1st injection: HB ≥ 10 g/dl (administration of 1st injection permitted if ≥ 8 g/dl), ANC ≥ 1.5 10^9 / L, platelets ≥ 100 10^9 / L.
  - Prior subsequent injections (2nd to 6th) ANC ≥ 110^9 / L, platelets ≥ 50 10^9 / L, HB ≥ 8 g/dl.

**EXCLUSIONS:**
- Contraindicated in combination with abiraterone acetate and prednisone/prednisolone
- Safety and efficacy of radium 223 in combination with cancer therapies other than LHRH analogues have not been established; an increased risk of mortality and fractures was demonstrated in combination with abiraterone and cannot be excluded with other. The combination of radium-223 with other systemic cancer therapies other than LHRH analogues is therefore not recommended.
- Chemotherapy administration within 4 weeks or planned concomitant administration
- Prior hembody irradiation or radio-isotope (strontium-89, samarium-153, rhenium-186 or rhenium-188) administration for bone metastases within 24 weeks
- Blood transfusion or erythropoietin administration within 4 weeks
- Presence of visceral metastases or extensive metastatic lymphadenopathies
- Prior treatment with radium-223
- Active spinal cord compression (including impending spinal cord compression, however previously treated spinal cord compression with recovery of mobility and a ECOG 0-2 does not constitute a contra-indication)
- Non-stabilised fracture
CAUTION IN USE:

- **Washout periods:**
  - Data on a safe period after which radium 223 can be administered following treatment with abiraterone acetate in combination with prednisone/prednisolone and vice versa is limited. Based on the elimination half-life of radium 223 and abiraterone, it is recommended that subsequent treatment with radium 223 is not initiated for at least 5 days after the last administration of abiraterone acetate in combination with prednisone/prednisolone.
  - Subsequent systemic cancer treatment should not be initiated for at least 30 days after the last administration of radium 223.

- **Treatment of patients with asymptomatic or mildly symptomatic bone metastases:** Radium 223 is not recommended for treatment of adults with castration-resistant prostate cancer and only asymptomatic bone metastases. In adults with castration-resistant prostate cancer and mildly symptomatic bone metastases the benefit of treatment should be carefully assessed to outweigh the risks considering that high osteoblastic activity is likely to be required for treatment benefit. The use of radium 223 in patients with a low level of osteoblastic bone metastases (evaluated by imaging or others) is not recommended.

- **Bone fractures:** Radium 223 increases the risk of bone fractures. Increased fracture risk has been found especially in patients with medical history of osteoporosis and in patients with less than 6 bone metastases. Other factors such as concomitant use of steroids may further increase the risk of fracture. Prior to starting radium-223 bone metastatic status (by imaging, e.g. by scintigraphy, and CT scan, evaluating extent of the metastatic bone disease and osteoblastic/clastic activity levels) and baseline patient individual risk of fractures evaluated by clinical criteria e.g. concomitant medication, low body mass index and others and imaging e.g. bone mineral density measurements) should be carefully assessed, and closely monitored for at least 24 months. Preventive measures such correction of risk factors and the use of bisphosphonates or denosumab should be considered before starting or resuming treatment with radium 223. In patients with a high baseline risk of fracture, the benefit of treatment should be carefully assessed to outweigh the risk. Orthopaedic stabilisation of fractures should be performed before starting or resuming treatment with Radium 223.

- **Patient with Crohn disease / Ulcerative colitis disease** should be carefully assessed.
  - Due to the faecal excretion of radium 223, radiation may lead to aggravation of acute inflammatory bowel disease. Radium 223 should only be administered after a careful benefit-risk assessment in patients with acute inflammatory bowel disease

PRESCRIPTIVE AUTHORITY:
The treatment plan must be initiated by a Consultant Radiation Oncologist with expertise in treatment of prostate cancer and radio-isotope prescription.

TESTS:

**Baseline tests:**
- Blood, renal and liver profile
- CT scan TAP/bone scan done within previous 12 weeks
- PSA and testosterone levels

**Regular tests:**
- FBC prior to each injection
Post therapy tests: FBC at 4 weeks post completion of therapy.

Disease monitoring:
Disease monitoring should be in line with the patient’s treatment plan and any other test/s as directed by the supervising Consultant.

DOSE MODIFICATIONS:
- No dose modification required, only delay injection to be considered.
- Any treatment delays should be discussed with a Consultant.

Haematological:
At time of the subsequent (2\textsuperscript{nd} to 6\textsuperscript{th}) injections, if haematological eligibility criteria are not fulfilled the injection should be delayed by 2-4 weeks. In the absence of haematological recovery after the latter delay, treatment should be discontinued.

Renal and Hepatic Impairment:

<table>
<thead>
<tr>
<th>Renal Impairment</th>
<th>Hepatic Impairment</th>
</tr>
</thead>
<tbody>
<tr>
<td>No dose adjustment/ treatment timing is considered</td>
<td>No dose adjustment/ treatment timing is considered</td>
</tr>
<tr>
<td>necessary in patients with renal impairment.</td>
<td>necessary in patients with renal impairment.</td>
</tr>
</tbody>
</table>

SUPPORTIVE CARE:

EMETOGENIC POTENTIAL: Low (Refer to local policy).

PREMEDICATIONS: None usually required.

OTHER SUPPORTIVE CARE:
Maintenance hormonal therapy (minimum GnRh agonist or orchidectomy required).
Biphosphonates/anti-RANKL antibody as directed by consultant.
Best supportive care (If indicated and left to consultant preference, e.g. analgesic medication, external beam radiation therapy, analgesics, external radiation therapy, etc.)

ADVERSE EFFECTS / REGIMEN SPECIFIC COMPLICATIONS
The adverse effects listed are not exhaustive. Please refer to the relevant Summary of Product Characteristics for full details.
This medicinal product is subject to additional monitoring. Healthcare professionals are asked to report any suspected adverse reactions.

- Bone marrow suppression: Bone marrow suppression, notably thrombocytopenia, neutropenia, leukopenia and pancytopenia, has been reported in patients treated with Radium 223. Haematological evaluation must be carried out at baseline and prior to every dose.
- Patients with evidence of compromised bone marrow reserve e.g. following prior cytotoxic chemotherapy and/or radiation treatment (EBRT) or prostate cancer patients with advanced diffuse infiltration of the bone (EOD4; “superscan”) should be treated with caution. An increased incidence of haematological adverse reactions such as neutropenia and thrombocytopenia was observed in these patients during the phase III study.
• **Crohn’s disease and ulcerative colitis**: Safety and efficacy of Radium 223 in patients with Crohn’s disease and with ulcerative colitis have not been studied. Due to the faecal excretion of Radium 223, radiation may lead to aggravation of acute inflammatory bowel disease. Radium 223 should only be administered after a careful benefit-risk assessment in patients with acute inflammatory bowel disease.

• **Spinal cord compression**: In patients with untreated imminent or established spinal cord compression, treatment with standard of care, as clinically indicated, should be completed before starting or resuming treatment with Radium 223.

• **Osteonecrosis of the jaw**: In patients treated with bisphosphonates and Radium 223, an increased risk of development of osteonecrosis of the jaw (ONJ) cannot be excluded.

• **Secondary malignant neoplasms**: Long-term cumulative radiation exposure may be associated with an increased risk of cancer and hereditary defects. In particular, the risk for osteosarcoma, myelodysplastic syndrome and leukaemias may be increased. No cases of Radium 223-induced cancer have been reported in clinical trials in follow-up of up to three years.

• **Excipients with known effect**: Depending on the volume administered, this medicinal product can contain up to 2.35 mmol (54 mg) sodium per dose. This should be taken into consideration by patients on a controlled sodium diet.

**DRUG INTERACTIONS:**

- No clinical interaction studies have been performed.
- As interactions with calcium and phosphate cannot be excluded, pausing supplementation with these substances and/or Vitamin D should be considered some days before starting with Radium 223 treatment.
- Concomitant chemotherapy with Radium 223 may have additive effects on bone marrow suppression
- Current drug interaction databases should be consulted for more information.

**ATC CODE:**

Radium 223 - V10XX03

**COMPANY SUPPORT RESOURCES/Useful Links:**

*Please note that this is for information only and does not constitute endorsement by the NCCP*

Xofigo – (radium-223-dichloride)-Important safety information from Bayer AG as approved by HPRA-March 2018.


**REFERENCES:**


<table>
<thead>
<tr>
<th>Version</th>
<th>Date</th>
<th>Amendment</th>
<th>Approved By</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>15/6/2015</td>
<td>Version 1</td>
<td>Dr Pierre Thirion</td>
</tr>
<tr>
<td>2</td>
<td>11/04/2016</td>
<td>Update of protocol to reflect Change in NIST Standard Reference Material. Clarification Regarding Hb levels</td>
<td>Dr Pierre Thirion</td>
</tr>
<tr>
<td>3</td>
<td>16/09/2016</td>
<td>Removal of reference to Orange label and clarification of reimbursement status</td>
<td>Dr Pierre Thirion</td>
</tr>
<tr>
<td>4</td>
<td>15/12/16</td>
<td>Revised wording to clarify the prescriptive authority requirement detailing that the treatment plan must be initiated by Consultant Radiation Oncologist with expertise in treatment of prostate cancer and radio-isotope prescription. Applied new NCCP regimen template</td>
<td>Dr Pierre Thirion</td>
</tr>
<tr>
<td>5</td>
<td>15/1/2018</td>
<td>Inclusion of Safety Notice from HPRA December 2017</td>
<td>Dr Pierre Thirion</td>
</tr>
<tr>
<td>6</td>
<td>16/4/2018</td>
<td>Updated exclusion criteria as per safety notice from HPRA March 2018 and clarified supportive care</td>
<td>Dr Pierre Thirion</td>
</tr>
<tr>
<td>7</td>
<td>21/10/2020</td>
<td>Updated to include EMA restrictions on use July 2018. Sections updated:</td>
<td>Dr Pierre Thirion</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Indication</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Eligibility, Inclusion/ Exclusion</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Caution in use</td>
<td></td>
</tr>
</tbody>
</table>

Comments and feedback welcome at oncologydrugs@cancercontrol.ie.

1ODMS – Oncology Drug Management System
CDS – Community Drug Schemes (CDS) including the High Tech arrangements of the PCRS community drug schemes
Further details on the Cancer Drug Management Programme is available at; http://www.hse.ie/eng/services/list/5/cancer/profinfo/medonc/cdmp/